Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag liqua.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag liqua.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag liqua.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag liqua.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Generating Human-relevant results with multiple endpoints
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Advanced multi-metric assessments
Nam tempor finibus lorem, nec varius arcu convallis sed. Nunc id orci a neque vehicula malesuada. Donec vehicula libero vel leo convallis, nec tincidunt felis tincidunt. Maecenas euismod tristique leo, vel malesuada ligula malesuada sed. Donec eget libero id leo congue venenatis.
Sed non massa sit amet sapien porttitor ornare.
Nullam vehicula magna sit amet magna ullamcorper, at dictum est gravida. Morbi nec magna at quam malesuada accumsan. Suspendisse potenti. Vivamus feugiat massa ut tortor scelerisque, non dapibus nulla consectetur. Aliquam erat volutpat.
Morbi nec magna at quam malesuada accumsan.
Etiam accumsan urna a mauris dapibus, nec aliquet nunc convallis. Phasellus eget justo et libero ultrices posuere. Cras euismod, arcu nec congue convallis, ipsum nunc cursus nibh, vel condimentum sapien orci non libero. Integer ullamcorper felis sit amet felis placerat, eu convallis lorem iaculis.
Phasellus eget justo et libero ultrices posuere.
Suspendisse potenti. Vivamus non arcu tincidunt, congue massa at, porttitor velit. Curabitur lacinia nisl ut turpis convallis, at dictum urna aliquet. Nullam non urna eget felis interdum feugiat. Morbi vel neque elit. Nullam a luctus leo. Integer maximus sapien in bibendum scelerisque.
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag liqua.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Making lung toxicity predictive, not reactive
This session highlighted where prediction fails today, the mechanistic gaps that limit current approaches, and how human NAMs can help close that gap. It also emphasised the key insights teams need to move from reactive findings to more proactive, informed decision-making.
De-risking nasal & pulmonary formulation development
To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.
Understanding off-target ADC lung toxicity: why human-relevant models matter
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
ImmuBYTES Session 3 Video Recording
DateCategory Watching Time 21 Minutes https://immuone.com/wp-content/uploads/2025/07/ImmuONE.mp4 Get in touch Add a Comment Related Posts
Looking beyond the baseline: new frontiers in lung and immune safety
In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.
Early detection of pulmonary ADC toxicity with high-content imaging of alveolar macrophages
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.